Evidence map›Paper›PMID 30666518›Full record

ArticlePathology oncology research : POR2019

Thyroid Carcinoma Coexisting with Hashimoto's Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis.

Csaba Molnár, Sarolta Molnár, Judit Bedekovics, Attila Mokánszki, Ferenc Győry, Endre Nagy, Gábor Méhes

Abstract read
In one paragraph

Article in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Csaba MolnárDepartment of Pathology, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4042, Hungary. molnar.csaba@med.unideb.hu.ORCID http://orcid.org/0000-0002-5428-7620
Sarolta MolnárDepartment of Pathology, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4042, Hungary.
Judit BedekovicsDepartment of Pathology, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4042, Hungary.
Attila MokánszkiDepartment of Pathology, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4042, Hungary.
Ferenc GyőryDepartment of Surgery, Clinical Center, University of Debrecen, Debrecen, Hungary.
Endre NagyDepartment of Internal Medicine, Clinical Center, University of Debrecen, Debrecen, Hungary.
Gábor MéhesDepartment of Pathology, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4042, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (TC) coexisting with Hashimoto's thyroiditis (HT) presents with several characteristic features including multifocality and lower clinical stages compared to de novo carcinomas but its exact biology is still not understood. We reexamined clinico-pathological and molecular correlations between Hashimoto's thyroditis and papillary thyroid cancer. A total of 262 patients with TC was evaluated who underwent thyroidectomy at the Surgical Department of the University of Debrecen. Clinical data, histology and molecular data were evaluated. Our cohort included 43 patients (16.4%) with (5 male, 38 female) and 219 (83.6%) patients without coexisting HT (48 male, 171 female). Hashimoto's thyroiditis related thyroid cancer presented predominantly (93.0% of the cases) with the papillary histological type. Multifocality was observed more frequently with coexisting HT (16/40; 40.0%) compared to cases uninvolved (45/190; 23.7%)(p = 0.034). In contrast, lymphatic metastasis (pN1) with a significantly reduced frequency in patients with HT (4/11; 36.4%) then without HT (34/41 pN1; 82.9%)(p = 0.002). BRAF V600E mutation could be demonstrated at significantly lower rates in cases of PTC + HT (32.1 vs 60.7%, p < 0.005). High incidence, multifocality and papillary morphology strongly support a causal relation between TC and preexisting Hashimoto's thyroiditis, the latter to be considered as a preneoplastic condition promoting thyroid carcinogenesis.

Indexed as

AdultFemaleFollow-Up StudiesHashimoto DiseaseHumansMaleMiddle AgedPrecancerous ConditionsPrognosisThyroid Cancer, PapillaryThyroidectomyThyroid NeoplasmsCarcinomaClinicopathologyHashimoto thyreoiditisMolecular pathologyThyroid

Identifiers

PMID30666518
PMCPMC6614143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.